Utomilumab

Phase 3Monoclonal antibody

Pfizer

Utomilumab is one of 200 biologic programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

199

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Advanced MalignanciesActive, not recruiting

Follicular LymphomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 1

Active, not recruiting

Advanced MalignanciesPhase 3

Active, not recruiting

Follicular LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Utomilumab

Pfizer

Phase 3

3 2

Tecentriq

Roche

Preclinical

36 3

Halaven

Eisai

Preclinical

38 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

Lexiscan

Astellas

Preclinical

1 8

Adenocard

Astellas

Preclinical

1 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 10

Zinecard

CChildren's Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Advanced Malignancies

NCT05059522

Clinical

Trials by Indication[1]

Breast Cancer3 trials

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Completed·—·Phase 1·NCT03364348·18 enrolled

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting·LLaura Huppert, MD, BA·Phase 2·NCT03971409·150 enrolled

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Active, not recruiting·—·Phase 2·NCT03414658·100 enrolled

Advanced Malignancies3 trials

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT02554812·409 enrolled

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03217747·173 enrolled

AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05059522·77 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02951156·29 enrolled

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Completed·—·Phase 1·NCT03440567·16 enrolled

Oropharyngeal Cancer1 trial

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03258008·3 enrolled

Metastatic Colorectal Cancer1 trial

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03290937·34 enrolled

3 more indications

Ovarian Cancer1 trial

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03318900·5 enrolled

Lymphoma1 trial

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

Terminated· Gilead logo

Gilead·Phase 1·NCT03704298·15 enrolled

Follicular Lymphoma1 trial

Rituximab + Immunotherapy in Follicular Lymphoma

Terminated·—·Phase 1·NCT03636503·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Utomilumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Utomilumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Utomilumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Utomilumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer3 trials

Advanced Malignancies3 trials

Diffuse Large B-Cell Lymphoma2 trials

Oropharyngeal Cancer1 trial

Metastatic Colorectal Cancer1 trial

Ovarian Cancer1 trial

Lymphoma1 trial

Follicular Lymphoma1 trial

References

Drug Info

Quick Facts

Related News